No Data
No Data
Companies Like Tourmaline Bio (NASDAQ:TRML) Are In A Position To Invest In Growth
Here's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Situation
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $63
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $63
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and Tourmaline Bio (TRML)